Shingles Vaccine Could Reduce Dementia Risk by up to 20 Percent
Shingles Vaccine Reduces Dementia Risk
A vaccination against shingles can reduce the risk of developing dementia by up to 20 percent, WELT reported based on recent scientific findings.
- New research links the shingles vaccine to a lower risk of dementia.
- Studies suggest chronic nervous system inflammation from viral infections may encourage abnormal protein deposits in the brain.
- Over 60 percent of the global population carries the herpes simplex virus type 1, which influences brain immune cells.
Researchers Link Viruses to Brain Inflammation
Chronic inflammation in the nervous system following viral infections is drawing intense focus from neurobiological researchers. Scientists warn that chronic inflammation in the brain may promote the buildup of harmful protein clumps. According to ad-hoc-news.de, the herpes simplex virus type 1 stands under heavy suspicion for involvement in brain diseases.
Investigations reveal that oral bacteria from conditions like periodontitis can also attack nerve cells directly through the bloodstream. Alongside careful oral hygiene, protective vaccinations have moved into sharp focus. Studies indicate that a vaccination against shingles can lower dementia risk by up to 20 percent.
Microglia’s Role Shifts After HSV-1 Exposure
The herpes simplex virus type 1 persists in the human body for a lifetime after an initial infection. A study from the University of Colorado Anschutz published in PLOS Pathogens shows that microglial cells in the brain shift into an active defense state following an HSV-1 infection. Experiments on mice at the university demonstrated that infected microglia might neglect their cellular waste removal functions, which potentially increases amyloid accumulations.
At the same time, the research showed no permanent damage and provided no definitive proof that cold sores directly cause Alzheimer’s disease. Dr. Hanul Bhandari from New Waters Recovery emphasized that direct causal proof for HSV-1 acting as a primary trigger remains absent. A systematic review from 2025 similarly classifies the evidence supporting this connection as limited.
Drugs and Trials Target Dementia’s Possible Causes
A meta-analysis involving over 10 million people demonstrated that treatments using antiviral herpes medications are associated with a lower risk of dementia, though causality was not established. Beyond viral pathogens, researchers are investigating bacterial triggers. A study by the University of Helsinki published in PLOS Medicine analyzed health data from more than 65,000 patients aged 65 and older.
Scientists are testing a small molecule designated as COR388, which remained stable in resistance screenings and continues under evaluation in clinical trials. Discussions around therapeutic interventions also involve dual-function inhibitors designed to suppress amyloid aggregation while exhibiting antibacterial properties. Researchers say preventive measures still matter just as much as medication. Consistent oral hygiene and protective vaccinations serve as foundational measures to minimize chronic bacterial stimuli early on.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.